AU2022275684A1 - Compositions for treatment of neurodegenerative conditions - Google Patents
Compositions for treatment of neurodegenerative conditions Download PDFInfo
- Publication number
- AU2022275684A1 AU2022275684A1 AU2022275684A AU2022275684A AU2022275684A1 AU 2022275684 A1 AU2022275684 A1 AU 2022275684A1 AU 2022275684 A AU2022275684 A AU 2022275684A AU 2022275684 A AU2022275684 A AU 2022275684A AU 2022275684 A1 AU2022275684 A1 AU 2022275684A1
- Authority
- AU
- Australia
- Prior art keywords
- triol
- ethynylandrost
- ene
- pharmaceutical composition
- several embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189880P | 2021-05-18 | 2021-05-18 | |
| US63/189,880 | 2021-05-18 | ||
| PCT/US2022/027294 WO2022245532A1 (en) | 2021-05-18 | 2022-05-02 | Compositions for treatment of neurodegenerative conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022275684A1 true AU2022275684A1 (en) | 2023-11-16 |
Family
ID=84141848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022275684A Pending AU2022275684A1 (en) | 2021-05-18 | 2022-05-02 | Compositions for treatment of neurodegenerative conditions |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240108636A1 (https=) |
| EP (1) | EP4341271A4 (https=) |
| JP (1) | JP2024519079A (https=) |
| AU (1) | AU2022275684A1 (https=) |
| CA (1) | CA3218191A1 (https=) |
| MX (1) | MX2023013616A (https=) |
| WO (1) | WO2022245532A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024054452A1 (en) * | 2022-09-06 | 2024-03-14 | Biovie Inc. | Methods for the treatment of mild cognitive impairment |
| WO2025155561A1 (en) * | 2024-01-16 | 2025-07-24 | Biovie Inc. | Methods of treating long covid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070015763A1 (en) * | 2005-07-12 | 2007-01-18 | Pfizer Inc | Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist |
| DK2273994T3 (en) * | 2008-04-03 | 2016-02-01 | Neurmedix Inc | PHARMACEUTICAL FORMS OF A MEDICINE |
-
2022
- 2022-05-02 EP EP22805164.5A patent/EP4341271A4/en active Pending
- 2022-05-02 MX MX2023013616A patent/MX2023013616A/es unknown
- 2022-05-02 JP JP2023571820A patent/JP2024519079A/ja active Pending
- 2022-05-02 AU AU2022275684A patent/AU2022275684A1/en active Pending
- 2022-05-02 CA CA3218191A patent/CA3218191A1/en active Pending
- 2022-05-02 WO PCT/US2022/027294 patent/WO2022245532A1/en not_active Ceased
-
2023
- 2023-11-16 US US18/511,027 patent/US20240108636A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023013616A (es) | 2024-01-17 |
| WO2022245532A1 (en) | 2022-11-24 |
| US20240108636A1 (en) | 2024-04-04 |
| EP4341271A1 (en) | 2024-03-27 |
| JP2024519079A (ja) | 2024-05-08 |
| EP4341271A4 (en) | 2025-04-30 |
| CA3218191A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021201390B2 (en) | Pharmaceutical compositions comprising glitazones and nrf2 activators | |
| US20240108636A1 (en) | Compositions for treatment of neurodegenerative conditions | |
| JP7557185B2 (ja) | 免疫応答を調節するｇａｂａの能力の強化 | |
| Quinn | Anti-parkinsonian drugs today | |
| JP2025510916A5 (https=) | ||
| EP2696864A1 (en) | Therapeutic compounds | |
| US20230066347A1 (en) | Ketamine treatment for amyotrophic lateral sclerosis | |
| JP2022507533A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| AU4748100A (en) | Glycine cleavage system inhibitors as potential antipsychotics | |
| WO2015162610A1 (en) | Cyclohexenyl compounds, compositions comprising them and uses thereof | |
| KR101851603B1 (ko) | 신경염증제어를 통한 파킨슨 질환 예방 또는 치료용 조성물 | |
| JP2014152175A (ja) | カテプシンｋ抑制剤としてミリセチンの用途 | |
| US9504679B2 (en) | Pharmaceutical compositions comprising glitazones and Nrf2 activators | |
| CN111265523A (zh) | 小檗碱、人参皂苷组合物在制备预防和/或治疗糖尿病伴发抑郁症的药物中的应用 | |
| CN108078984B (zh) | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 | |
| JP2011178702A (ja) | 睡眠の改善剤 | |
| KR102346790B1 (ko) | 콜히친과 메트포르민을 유효성분으로 하는 항비만 치료제 | |
| Yugesh et al. | ACETYLCYSTEINE AND ACEBROPHYLLINE FIXED DOSE COMBINATION CHRONOTHERAPY FOR COPD AND NOCTURNAL ASTHMA | |
| US11452704B2 (en) | Prevention and treatment of muscle wasting with ketone supplementation | |
| AU2018426503A1 (en) | Pharmaceutical composition for preventing diabetes and use thereof | |
| EA017090B1 (ru) | Комбинация модафинила и 1-{3-[3-(4-хлорфенил)пропокси]пропил}пиперидина | |
| CN106138031A (zh) | 桑辛素c在制备用于治疗糖尿病的药物中的应用 | |
| CN107951872B (zh) | 一种治疗糖尿病的口服药物组合物 | |
| KR20240070564A (ko) | 알츠하이머병 예방 또는 치료용 약학적 조성물 | |
| CN103919776B (zh) | 一种治疗关节炎的药物组合物 |